



MOREPEN

Date: 09/08/2016

To,

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Tel No: (022) 26598100 - 8114
Fax No: (022) 26598120
Symbol: MOREPENLAB

BSE Limited
Floor 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Phones: 91-22-22721233/4
Fax: 91-22-2272 3121
Scrip Code: 500288

Subject: Outcome of the meeting of the Board of Directors of the Company held on 09th August, 2016

Dear Sir,



This is to inform you that the Board of Directors of the Company, in their meeting held on 09th August, 2016, have inter-alia considered and approved the Un-Audited Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 30th June, 2016, along with Limited Review Report of the Auditors thereon (*Copy enclosed*).

Kindly acknowledge the receipt and take it on your record.

Thanking you.

Yours faithfully,

For **Morepen Laboratories Limited**



(Thomas P. Joshua)
Company Secretary

Encl.: As Above

Morepen Laboratories Limited

Corp. Off.: 4th Floor, Antriksh Bhawan, 22 K.G.Marg, New Delhi - 110 001, INDIA
Tel.: +91-11-23324443, 23712025, E-mail: corporate@morepen.com, Website: www.morepen.com
CIN NO. L24231 HP1984PLC006028


Plant & Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205
Tel.: +91-1795-266401-03, 244590, Fax: +91-1795-244591, E-mail: plants@morepen.com

CHARTERED ACCOUNTANTS

**Review Report to
The Board of Directors
Morepen Laboratories Limited
New Delhi**


1. We have reviewed the accompanying statement of unaudited financial results of **Morepen Laboratories Limited**, ("the company") for the quarter ended June 30, 2016 (the "Statement"). This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement .

For M. Kamal Mahajan And Co.
Chartered Accountants
(Firm Regn No. 006855N)


(Manik Bansal)

Partner

Membership No. 422936



Place : New Delhi
Date: August 09 ,2016

Morepen Laboratories Limited
CIN- L24231HP1984PLC006028
Statement of Standalone Unaudited Financial Results
For the Quarter Ended 30th June, 2016

Particulars		(Rs.in Lacs)			
		Quarter Ended			Year Ended
		30.06.2016	31.03.2016	30.06.2015	31.03.2016
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1(a)	Net Sales/Income from Operations (Net of Excise Duty)	11672.41	11977.21	9927.56	43669.21
(b)	Other Operating Income	171.59	382.10	428.35	1577.09
	Total Income from Operations (Net)	11844.00	12359.31	10355.91	45246.30
2	Expenditure				
	a) Cost of Material Consumed	5211.99	4492.76	4310.45	18159.46
	b) Purchase of stock - in - trade	2843.24	2722.84	2329.76	10226.71
	c) Changes in inventories of Finished goods, Work -in- progress and Stock-in-trade	(601.15)	387.08	(224.26)	(445.60)
	d) Employee benefits expenses	1311.47	1401.02	1215.77	5166.65
	e) Depreciation and Amortisation	835.25	877.16	867.50	3492.18
	f) Power and Fuel	222.65	159.63	189.63	763.66
	g) Travelling Expenses	191.15	168.69	148.83	608.67
	h) Selling and Distribution Expenses	617.22	548.48	516.37	1986.92
	i) Other Expenses	609.29	684.17	523.10	2359.50
	Total Expenditure	11241.11	11441.83	9877.15	42318.15
3	Profit from Operations before Other Income, Finance Cost and Exceptional Items (1-2)	602.89	917.48	478.76	2928.15
4	Other Income /(Loss)	-	67.83	15.62	117.24
5	Profit from Ordinary activities before Finance Cost and Exceptional Items (3+4)	602.89	985.31	494.38	3045.39
6	Finance Cost	201.56	268.45	181.58	1041.29
7	Profit from Ordinary activities after Finance Cost but before Exceptional Items (5-6)	401.33	716.86	312.80	2004.10
8	Exceptional Items - Income/(Expense)	-	-	-	-
9	Profit from Ordinary Activities before Tax (7+8)	401.33	716.86	312.80	2004.10
10	Tax Expense	85.64	80.14	62.58	337.68
	MAT Credit	(85.64)	(80.14)	-	(337.68)
	Income Tax - Earlier period	-	-	-	(13.70)
11	Profit from Ordinary Activities after Tax (9-10)	401.33	716.86	250.22	2017.80
12	Extraordinary Items-Income/(Expense)	-	(440.00)	-	(440.00)
13	Net Profit for the period after Tax (after Extraordinary Items) (11+12)	401.33	276.86	250.22	1577.80
14	Paid-up Equity Share Capital of Face Value of Rs.2/- each	8995.86	8995.86	8995.86	8995.86
15	Reserves excluding Revaluation reserve	-	-	-	11924.40
16	a) Earning Per Share before Extraordinary Items (in Rs.) * Basic & Diluted	0.09	0.16	0.05	0.45
	b) Earning Per Share after Extraordinary Items (in Rs.) * Basic & Diluted	0.09	0.06	0.05	0.35

*After considering dividend on cumulative preference shares.

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 9, 2016. A limited review of the same has been carried out by the Statutory Auditors.
2. The Company is engaged in the Pharmaceutical Business Segment.
3. Consolidated Income from Operations, Net Profit/ (Loss), EPS for the quarter ended June 30, 2016 stands at Rs. 12995.37 Lacs, Rs. 401.09 Lacs & Rs. 0.09 respectively.

For and on behalf of the Board of Directors of Morepen Laboratories Limited

Place : New Delhi
Date : August 9, 2016



(Sushil Suri)
 Chairman & Managing Director